Revenue has been lumpy, peaking at $19.1M in 2025Q3 and reaching $18.7M in 2026Q2, while operating margin remained negative at -18.7% and net margin at -34.1% in the latest quarter.
Xilio Therapeutics, Inc. (XLO) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 55.01M | 43.77M | 6.34M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 72.97% | 589.88% | - | - | - | - | - | - |
| Cost of Goods Sold | 344K | 1.54M | 0 | 0 | 0 | 1.5M | 1.06M | 240K |
| COGS % of Revenue | - | 3.52% | - | - | - | - | - | - |
| Gross Profit | 54.67M | 42.23M | 6.34M | 0 | 0 | -1.5M | -1.06M | -240K |
| Gross Margin % | 99.37% | 96.48% | 100% | - | - | - | - | - |
| Gross Profit Growth % | - | 565.59% | - | - | 100% | -40.75% | -343.75% | - |
| Operating Expenses | 95.85M | 84.21M | 66.93M | 79.13M | 89.15M | 73.55M | 53.5M | 18.79M |
| OpEx % of Revenue | - | 192.4% | 1054.95% | - | - | - | - | - |
| Selling, General & Admin | 28.54M | 29.71M | 24.78M | 27M | 29.95M | 22.36M | 9.59M | 4.53M |
| SG&A % of Revenue | - | 67.88% | 390.57% | - | - | - | - | - |
| Research & Development | 67.32M | 56.04M | 41.21M | 52.14M | 59.2M | 51.19M | 43.91M | 14.26M |
| R&D % of Revenue | - | 128.04% | 649.61% | - | - | - | - | - |
| Other Operating Expenses | 0 | -1.54M | 937K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -41.19M | -41.98M | -60.58M | -79.13M | -89.15M | -75.04M | -54.56M | -19.03M |
| Operating Margin % | -74.87% | -95.92% | -954.95% | - | - | - | - | - |
| Operating Income Growth % | - | 30.7% | 23.44% | 11.24% | -18.8% | -37.54% | -186.77% | - |
| EBITDA | -39.87M | -40.44M | -58.94M | -77.23M | -87.3M | -73.55M | -53.5M | -18.79M |
| EBITDA Margin % | -72.48% | -92.4% | -929.04% | - | - | - | - | - |
| EBITDA Growth % | 5.48% | 31.38% | 23.69% | 11.53% | -18.71% | -37.47% | -184.76% | - |
| D&A (Non-Cash Add-back) | 1.32M | 1.54M | 1.64M | 1.9M | 1.85M | 1.5M | 1.06M | 240K |
| EBIT | -11.49M | -35.04M | -59.65M | -76.4M | -88.22M | -75.2M | -54.62M | -17.31M |
| Net Interest Income | 0 | 3.4M | -100K | 0 | 0 | -599.4K | -599.4K | 0 |
| Interest Income | 0 | 3.4M | 0 | 0 | 0 | 600 | 600 | 0 |
| Interest Expense | 0 | 0 | 100K | 0 | 0 | 600K | 600K | 0 |
| Other Income/Expense | 29.7M | 6.95M | 2.34M | 2.73M | 927K | -756K | -656K | 1.72M |
| Pretax Income | -11.49M | -35.04M | -58.24M | -76.4M | -88.22M | -75.8M | -55.22M | -17.31M |
| Pretax Margin % | -20.89% | -80.05% | -918.05% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.49M | -35.04M | -58.24M | -76.4M | -88.22M | -75.8M | -55.22M | -17.31M |
| Net Margin % | -20.89% | -80.05% | -918.05% | - | - | - | - | - |
| Net Income Growth % | 80.36% | 39.84% | 23.77% | 13.4% | -16.39% | -37.27% | -218.98% | - |
| Net Income (Continuing) | -11.49M | -35.04M | -58.24M | -76.4M | -88.22M | -75.8M | -55.22M | -17.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.58 | -4.19 | -15.26 | -38.92 | -45.08 | -189.28 | -1475.88 | -592.06 |
| EPS Growth % | 96.43% | 72.54% | 60.79% | 13.66% | 76.18% | 87.18% | -149.28% | - |
| EPS (Basic) | - | -4.19 | -15.26 | -38.92 | -45.08 | -189.28 | -1475.88 | -592.06 |
| Diluted Shares Outstanding | 19.69M | 8.36M | 3.82M | 1.96M | 1.96M | 400.45K | 37.41K | 29.24K |
| Basic Shares Outstanding | 19.69M | 8.36M | 3.82M | 1.96M | 1.96M | 400.45K | 37.41K | 29.24K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying XLO stock.
For fiscal year 2025, Xilio Therapeutics, Inc. (XLO) reported total revenue of $43.8M.
Xilio Therapeutics, Inc. (XLO) reported a net loss of $35.0M for the fiscal year ending 2025.
Xilio Therapeutics, Inc. (XLO) reported an operating income of $-42.0M, resulting in an operating profit margin of -95.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Xilio Therapeutics, Inc. (XLO) generated $42.2M in gross profit for the year, representing a gross profit margin of 96.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Revenue volatility and persistent operating losses
Metrics are mathematically derived from official filings.
Lumpy Collaboration Revenue Drives Growth
Based on the reported quarterly income statements, XLO's revenue swung from $2.9M in 2025Q1 to $19.1M in 2025Q3 before falling to $12.6M in 2026Q1, a pattern that points to milestone or collaboration recognition rather than a steady commercial base.
The 131.2% sequential jump to $18.7M in 2026Q2 following a 3.3% gain in the prior quarter suggests revenue is being recognized in discrete tranches rather than accruing from recurring sales. Because no product revenue is visible in the supplied data, investors should monitor whether these inflows reflect durable partnership economics or one-time recognition events. The absence of a consistent trend makes growth durability difficult to assess from reported figures alone.
Operating Losses Persist Despite Revenue Gains
As reported in the income statements, XLO's operating loss narrowed to -$3.5M in 2026Q2 from -$14.1M in 2026Q1, yet R&D spend of $14.6M and SG&A of $7.6M still exceeded the $18.7M revenue base, leaving operating margin at -18.7%.
The improvement in operating income appears driven primarily by the revenue spike rather than by any structural cost reduction, since R&D remained elevated relative to revenue across most periods. Operating leverage is therefore positive only in the sense that a high-revenue quarter temporarily offsets an otherwise fixed cost base. Investors should watch whether R&D intensity declines as revenue normalizes, as sustained losses at current spend levels would warrant further investigation.
Net Income Diverges Sharply From Operating Results
Based on the reported figures, XLO posted a net income of $10.4M in 2025Q4 despite an operating loss of -$11.8M, a gap of roughly $22M that the supplied data does not explain and that warrants further investigation.
A positive net result against a deeply negative operating line typically reflects non-operating items such as investment gains, financing-related adjustments, or tax effects, but the supplied data does not disclose their composition. EPS swings from -$1.54 to +$0.81 across adjacent quarters reinforce that reported earnings are heavily influenced by items outside core operations. Investors should treat reported EPS as a noisy indicator of underlying operating performance.
R&D Dominates the Cost Structure
According to the reported quarterly data, R&D expense ranged from $8.3M to $19.8M over the ten quarters, consistently exceeding SG&A and representing the largest operating cost line for XLO throughout the period.
R&D intensity relative to revenue remains very high, which is typical of clinical-stage biotechnology but leaves limited margin for error if collaboration income slows. SG&A has remained comparatively stable between roughly $5.8M and $8.5M, suggesting overhead discipline, though it does not offset the research burden. Stock-based compensation of $1.1M to $2.9M per quarter is modest relative to total operating expense and does not appear to be a principal driver of the loss profile.
Revenue Recognition Could Mask Underlying Weakness
The strongest challenge to XLO's recent improvement is that the 2026Q2 revenue spike of $18.7M may be non-recurring, and that gross profit of $18.7M against zero COGS could overstate the business's sustainable economics.
Collaboration revenue recognized in a single quarter can create the appearance of a turnaround that reverses when milestone payments conclude, as the 2025Q2 quarter with negative gross profit of -$7.2M illustrates. Peer comparisons show XLO's operating margin profile is weak relative to RCUS and TGTX, which have established revenue bases. Investors should assess whether quarterly volatility reflects structural strength or episodic recognition before extrapolating recent results.